Safety and efficacy of initiation SGLT in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease on top of standard therapy with ARNI or ACE-i

dc.contributor.author	Obertynska, O.	en
dc.contributor.author	Rasputina, L.	en
dc.date.accessioned	2025-03-13T11:36:43Z
dc.date.available	2025-03-13T11:36:43Z
dc.date.issued	2024
dc.identifier.citation	Obertynska O. Safety and efficacy of initiation SGLT in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease on top of standard therapy with ARNI or ACE-i / O. Obertynska, L. Rasputina // European Heart Journal. – 2024. – Vol. 45, № 1.	en
dc.identifier.other	DOI: 10.1093/eurheartj/ehae666.1041
dc.identifier.uri	https://dspace.vnmu.edu.ua/123456789/7529	en
dc.description.abstract	Quadruple therapy remains underused in cases of heart failure with a reduced ejection fraction (HFrEF). Among eligible patients most of them take ACE-i/ARB and B-blockers, less MRAs and ARNI. There are many questions of adding new foundational drugs, especially in the case of coexisting of HFrEF and chronic kidney disease (CKD). The aim was to compare the safety and effectiveness of initiation SGLT in patients (P) with HFrEF and CKD on standard therapy with ARNI or ACE-I.	en
dc.language.iso	en	en
dc.publisher	European Heart Journal	en
dc.subject	chronic kidney disease	en
dc.subject	SGLT	en
dc.subject	heart failure	en
dc.title	Safety and efficacy of initiation SGLT in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease on top of standard therapy with ARNI or ACE-i	en
dc.type	Thesis	en